OBJECTIVE: : Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment. Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments. In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission. METHOD: : One hundred sixty-eight children and adolescents, ages 7 to 18 years, with primary diagnoses of major depressive disorder received 12 weeks of fluoxetine treatment. The youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. RESULTS: : Positive first-degree family history of depression was the only baseline demographic and clinical characteristic that predicted a favorable treatment response (p =.01). The rate of symptom improvement, however, is a good indicator of acute treatment response. A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment. CONCLUSIONS: : This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission. Treatment approach may be reevaluated and modified as early as week 4 during acute treatment.Clinical trials registration information-Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00332787.
OBJECTIVE: : Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment. Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments. In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission. METHOD: : One hundred sixty-eight children and adolescents, ages 7 to 18 years, with primary diagnoses of major depressive disorder received 12 weeks of fluoxetine treatment. The youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children's Depression Rating Scale-Revised. RESULTS: : Positive first-degree family history of depression was the only baseline demographic and clinical characteristic that predicted a favorable treatment response (p =.01). The rate of symptom improvement, however, is a good indicator of acute treatment response. A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment. CONCLUSIONS: : This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission. Treatment approach may be reevaluated and modified as early as week 4 during acute treatment.Clinical trials registration information-Determining Optimal Continuation Treatment Duration for DepressedChildren and Adolescents. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00332787.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: A L Brody; S Saxena; D H Silverman; S Alborzian; L A Fairbanks; M E Phelps; S C Huang; H M Wu; K Maidment; L R Baxter Journal: Psychiatry Res Date: 1999-10-11 Impact factor: 3.222
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: Taryn L Mayes; Ira H Bernstein; Charlotte L Haley; Betsy D Kennard; Graham J Emslie Journal: J Child Adolesc Psychopharmacol Date: 2010-12 Impact factor: 2.576
Authors: Rongrong Tao; Graham J Emslie; Taryn L Mayes; Paul A Nakonezny; Betsy D Kennard Journal: J Child Adolesc Psychopharmacol Date: 2010-10 Impact factor: 2.576
Authors: Paul A Nakonezny; Carroll W Hughes; Taryn L Mayes; Kathryn H Sternweis-Yang; Betsy D Kennard; Matthew J Byerly; Graham J Emslie Journal: J Child Adolesc Psychopharmacol Date: 2010-10 Impact factor: 2.576
Authors: Bret R Rutherford; Joel R Sneed; Jane M Tandler; David Rindskopf; Bradley S Peterson; Steven P Roose Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-06-15 Impact factor: 8.829
Authors: Dana L McMakin; Thomas M Olino; Giovanna Porta; Laura J Dietz; Graham Emslie; Gregory Clarke; Karen Dineen Wagner; Joan R Asarnow; Neal D Ryan; Boris Birmaher; Wael Shamseddeen; Taryn Mayes; Betsy Kennard; Anthony Spirito; Martin Keller; Frances L Lynch; John F Dickerson; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-03-03 Impact factor: 8.829